Literature DB >> 1732009

Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.

M J Niedbala1, M S Picarella.   

Abstract

Tumor necrosis factor (TNF) has a profound capacity to alter the endothelial cell phenotype that includes morphologic and functional changes that may be central for proinflammatory processes. Recent observations have indicated that TNF can promote the synthesis and secretion of urokinase plasminogen activator (uPA) in low passage human endothelial cells that normally release little uPA. In this report we have confirmed and expanded upon these initial observations in human endothelial cells and describe the ability of gamma-interferon (gamma-IFN) to inhibit TNF-induced uPA synthesis and secretion in a dose-dependent manner (0.025 to 25 ng/mL). Analysis of cell-free conditioned medium derived from gamma-IFN-treated cultures by micro-enzyme-linked immunosorbent assay (ELISA) methodologies using uPA- and plasminogen activator inhibitor type 1 (PAI-1)-specific monoclonal antibodies (MoAbs) indicate that the decrease in uPA activity observed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography is a direct result of a decrease in extracellular uPA antigen and is not a consequence of increased PAI-1 antigen. These findings are supported by Northern blot analyses that indicate that gamma-IFN treatment of endothelial cells resulted in a decreased steady state level of uPA messenger RNA (mRNA) with no measurable change in PAI-1 mRNA. This inhibitory response is specific for gamma-IFN because alpha-IFN fails to elicit a similar inhibitory response. In addition, TNF augmented extracellular proteolysis of radiolabeled subendothelial extracellular matrix (ECM) in a dose-dependent manner. The observed increase in ECM degradation mediated by TNF treatment of endothelial cells was dependent on the presence of plasminogen and could be inhibited by an anticatalytic uPA MoAb implying the requirement of proteolytically active uPA in this process. gamma-IFN (25 ng/mL) treatment of endothelial cells antagonized TNF-promoted degradation of radiolabeled ECM at a concentration that completely inhibited TNF-mediated uPA expression and activity. In addition, endothelial cells treated with TNF (18 hours) displayed the ability to invade ECM and reorganize individual cells into tube-like structures that were not evident in untreated control cultures when grown on Matrigel-coated culture dishes. gamma-IFN treatment of endothelial cells propagated on Matrigel was observed to inhibit TNF-mediated ECM invasion and tube formation at concentrations that were analogous to those required for the inhibition of uPA expression and activity. In summary, these observations suggest a novel homeostatic control mechanism for endothelial cell regulation of subendothelial ECM degradation promoted by TNF and inhibited by gamma-IFN.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732009

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Phenotypic modulation of cultured endothelial cells in collagen matrices induced by tumor necrosis factor alpha.

Authors:  S Nakatani; L Lu; N Okada; K Yoshikawa
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-03       Impact factor: 2.416

2.  The effect of the fibrinolytic enzyme FIIa from Agkistrodon acutus venom on acute pulmonary thromboembolism.

Authors:  Xi Lin; Xiu-xia Liang; Jian-jun Tang; Jia-shu Chen; Peng-xin Qiu; Guang-mei Yan
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

3.  In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis.

Authors:  I K Mullarky; F M Szaba; C G Winchel; M A Parent; L W Kummer; N Mackman; L L Johnson; S T Smiley
Journal:  J Thromb Haemost       Date:  2006-07       Impact factor: 5.824

4.  Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms.

Authors:  Suraj Kachgal; Andrew J Putnam
Journal:  Angiogenesis       Date:  2010-11-21       Impact factor: 9.596

5.  Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

6.  Interleukin-4 Modulation of Platelet-Derived Growth Factor-Induced Smooth Muscle Cell Urokinase Plasminogen Activator.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

7.  Plasminogen activation in epiretinal membranes.

Authors:  I Immonen; A Vaheri; P Tommila; V Sirén
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-11       Impact factor: 3.117

8.  G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.

Authors:  X H Pei; Y Nakanishi; K Takayama; F Bai; M Kawasaki; N Hara
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

9.  Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity.

Authors:  P Koolwijk; M G van Erck; W J de Vree; M A Vermeer; H A Weich; R Hanemaaijer; V W van Hinsbergh
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

10.  Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.

Authors:  C Trân-Thang; E Kruithof; H Lahm; W A Schuster; M Tada; B Sordat
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.